XERSHealthcare · Drug Manufacturers - Specialty & GenericThe 7 Wall Street analysts covering Xeris Biopharma Holdings, Inc. hold a median 12-month price target of $12 — +14.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 27 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Xeris Biopharma Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (98): The business earns solid, repeatable profits on what it owns.
Issuance (15): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on XERS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +14.8% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Oct 2026 | Barclays | Maintains | Overweight | $12 → $14 |
| 10 Sept 2026 | Leerink Partners | Maintains | Outperform | $12 → $16 |
| 10 Sept 2026 | Leerink Partners | Maintains | Outperform | — |
| 20 Aug 2026 | Barclays | Maintains | Overweight | — |
| 20 Aug 2026 | Barclays | Maintains | Overweight | $9.00 → $12 |
| 2 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | $10 |
| 2 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Dec 2025 | Barclays | Initiates | Overweight | — |
| 7 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Nov 2025 | Oppenheimer | Maintains | Outperform | — |
| 7 Nov 2025 | Piper Sandler | Maintains | Neutral | — |
| 29 Oct 2025 | Oppenheimer | Maintains | Outperform | — |
| 17 Sept 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Aug 2025 | Leerink Partners | Maintains | Outperform | — |
| 12 Aug 2025 | HC Wainwright & Co. | Assumes | Buy | $10 |
| 8 Aug 2025 | Craig-Hallum | Maintains | Buy | — |
| 8 Aug 2025 | Oppenheimer | Maintains | Outperform | — |
| 5 June 2025 | Leerink Partners | Maintains | Outperform | — |
| 9 May 2025 | Oppenheimer | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
XERS appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, Xeris Biopharma Holdings, Inc. returned +12.2% against +13.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 6% of US stocks
Cheaper than 21% of US stocks
Cheaper than 99% of US stocks
Cheaper than 6% of US stocks
Higher than 77% of US stocks
Higher than 65% of US stocks
Higher than 95% of US stocks
Higher than 56% of US stocks
Higher than 24% of US stocks
Higher than 52% of US stocks
Higher than 82% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Xeris Biopharma Holdings, Inc. has a market value of $1.9B and an enterprise value of $2.0B.
Revenue in the twelve months to 30 June 2026: $335.4M. The latest quarter grew 28.7% year on year.
Net income over the same four quarters: −$17.2M, a −5.1% net margin.
Diluted earnings per share, trailing twelve months: $−0.11.
Free cash flow in the twelve months to 30 June 2026: $55.7M, after $938K of capital spending.
Xeris Biopharma Holdings, Inc. spent $19.2M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 117.6×; forward P/E: 53.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Xeris Biopharma Holdings, Inc. employs 435 people — $771K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Xeris Biopharma Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Xeris Biopharma said it will release its third-quarter 2026 financial results and business highlights before U.S. markets open on November 5, 2026. Management will host a conference call.
Why it matters — XERS watchers will receive the company’s quarterly results and business update on the announced date.
Xeris Biopharma said it will disclose data spanning its commercial portfolio and pipeline at multiple scientific meetings, reinforcing its focus on endocrinology.
Why it matters — The disclosures bring attention to data across Xeris’s marketed products and development pipeline.
On October 1, 2026, Xeris Biopharma's Compensation Committee granted non-qualified stock options and restricted stock units for an aggregate of 352,170 shares of common stock to 60 new employees under its Inducement Equity Plan. The grants were made under NASDAQ Listing Rule 5635(c)(4).
Why it matters — The inducement grants signal hiring activity and equity-based compensation tied to new employees, which affects Xeris' share count and dilution outlook for investors watching the company.
Bloomberg News reported, citing people familiar with the matter, that Danish drugmaker H Lundbeck A/S has expressed interest in acquiring Chicago-based Xeris Biopharma. The news was reported on Tuesday.
Why it matters — Acquisition interest from a larger pharmaceutical company could signal potential value or a change of ownership for Xeris Biopharma shareholders.
Xeris Biopharma Holdings discussed its XP-8121 program overview, Phase 3 study details, and commercial strategy in a transcript, as reported by Seeking Alpha. The item outlines company commentary on the program's development and market plans.
Why it matters — XERS watchers would care because the discussion provides insight into the company's progress and plans for its advanced XP-8121 pipeline candidate.
The 7 Wall Street analysts covering Xeris Biopharma Holdings, Inc. have a median 12-month price target of $12, with estimates ranging from $8 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Xeris Biopharma Holdings, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xeris Biopharma Holdings, Inc. 85 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 27 Oct 2026, Xeris Biopharma Holdings, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +14.8% from the last close, and Ticker Nerd's factor model ranks Xeris Biopharma Holdings, Inc. 85 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Xeris Biopharma Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XERS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $18 over the next 12 months.
Xeris Biopharma Holdings, Inc. returned +12.2% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for chronic endocrine and neurological diseases.
The most recent item we track (Business Wire, 22 Oct 2026): "Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026". Xeris Biopharma said it will release its third-quarter 2026 financial results and business highlights before U.S. markets open on November 5, 2026. Management will host a conference call.
Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for chronic endocrine and neurological diseases. Xeris Biopharma Holdings, Inc. markets Gvoke, a ready-to-use liquid glucagon for severe hypoglycemia; Keveyis, a treatment for primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for endogenous hypercortisolemia associated with Cushing’s syndrome. The company also works with proprietary formulation technologies designed to support liquid-stable, ready-to-use injectable medicines and reduce preparation steps for patients and caregivers. Its business is centered on specialty pharmaceuticals that address complex, often long-term conditions in endocrinology, neurology, and related areas, with a focus on patient-friendly delivery formats and commercial therapies already in market.
CEO Mr. John P. Shannon · 435 employees · United States · https://www.xerispharma.com
